Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 15

1.

A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.

Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC Jr, Skates SJ.

Gynecol Oncol. 2009 Jan;112(1):40-6. doi: 10.1016/j.ygyno.2008.08.031. Epub 2008 Oct 12.

2.

HE4--a novel promising serum marker in the diagnosis of ovarian carcinoma.

Langmár Z, Németh M, Vleskó G, Király M, Hornyák L, Bösze P.

Eur J Gynaecol Oncol. 2011;32(6):605-10. Review.

PMID:
22335019
3.

New tumor markers: CA125 and beyond.

Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K.

Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81. Review.

PMID:
16343244
4.

[Ovarian tumor markers of presumed benign ovarian tumors].

Lahlou N, Brun JL.

J Gynecol Obstet Biol Reprod (Paris). 2013 Dec;42(8):752-9. doi: 10.1016/j.jgyn.2013.09.030. Epub 2013 Nov 7. Review. French.

5.

HE4 in ovarian cancer: from discovery to clinical application.

Montagnana M, Danese E, Giudici S, Franchi M, Guidi GC, Plebani M, Lippi G.

Adv Clin Chem. 2011;55:1-20. Review.

PMID:
22126021
6.

HE4 as a biomarker for ovarian and endometrial cancer management.

Li J, Dowdy S, Tipton T, Podratz K, Lu WG, Xie X, Jiang SW.

Expert Rev Mol Diagn. 2009 Sep;9(6):555-66. doi: 10.1586/erm.09.39. Review.

7.

Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review.

Ferraro S, Braga F, Lanzoni M, Boracchi P, Biganzoli EM, Panteghini M.

J Clin Pathol. 2013 Apr;66(4):273-81. doi: 10.1136/jclinpath-2012-201031. Epub 2013 Feb 20. Review.

PMID:
23426716
8.

[Serum tumor markers CA125 and HE4 in ovarian cancer patients].

Sergeeva NS, Marshutina NV, Alentov II, Korneeva IA, Novikova EG.

Vopr Onkol. 2013;59(2):12-21. Review. Russian. No abstract available.

PMID:
23814844
9.

Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and meta-analysis.

Lin J, Qin J, Sangvatanakul V.

Eur J Obstet Gynecol Reprod Biol. 2013 Mar;167(1):81-5. doi: 10.1016/j.ejogrb.2012.10.036. Epub 2012 Dec 7. Review.

PMID:
23228410
10.

Human epididymis protein 4 (HE4) in laboratory medicine and an algorithm in renal disorders.

Kappelmayer J, Antal-Szalmás P, Nagy B Jr.

Clin Chim Acta. 2015 Jan 1;438:35-42. doi: 10.1016/j.cca.2014.07.040. Epub 2014 Aug 13. Review.

PMID:
25127713
11.

The Role of CA 125 as Tumor Marker: Biochemical and Clinical Aspects.

Bottoni P, Scatena R.

Adv Exp Med Biol. 2015;867:229-44. doi: 10.1007/978-94-017-7215-0_14. Review.

PMID:
26530369
12.

Detection and monitoring of ovarian cancer.

Su Z, Graybill WS, Zhu Y.

Clin Chim Acta. 2013 Jan 16;415:341-5. doi: 10.1016/j.cca.2012.10.058. Epub 2012 Nov 16. Review.

PMID:
23165217
13.

Biomarker testing for ovarian cancer: clinical utility of multiplex assays.

Nolen BM, Lokshin AE.

Mol Diagn Ther. 2013 Jun;17(3):139-46. doi: 10.1007/s40291-013-0027-6. Review.

14.

Current state of biomarker development for clinical application in epithelial ovarian cancer.

Moore RG, MacLaughlan S, Bast RC Jr.

Gynecol Oncol. 2010 Feb;116(2):240-5. doi: 10.1016/j.ygyno.2009.09.041. Epub 2009 Oct 31. Review.

15.

Is HE4 serum level a valid screening test in women candidates for kidney transplant? A case report and a review of literature.

Romeo V, Framarino Dei Malatesta M, Nudo F, Simonelli L, Derme M, Berloco PB.

Clin Ter. 2014;165(2):e162-5. doi: 10.7471/CT.2014.1702. Review.

PMID:
24770827
Items per page

Supplemental Content

Write to the Help Desk